Will the FDA Regulate Just Genetic Risk Data, or All Risk Data?
The latest in the 23andme versus FDA saga, in which the FDA halted 23andme from offering health-risk analyses of the genotyping service the company sells, comes...
The latest in the 23andme versus FDA saga, in which the FDA halted 23andme from offering health-risk analyses of the genotyping service the company sells, comes...
The company announced today that in reaction to the FDA’s order to marketing health-related information based on its genetic testing, it will cease provid...
One of the key issues in the dust-up over the FDA’s insistence on regulating 23andMe’s service is the question of how 23andMe’s health-risk r...
Below find my ever-growing annotated collection of online responses to the FDA’s recent shot across the bow of 23andMe, the consumer genetics company. Unt...
Here’s a particularly sharp, context-rich post on that question from from Margaret Curnutte, currently of Baylor University. It seems one of the more dee...
In the world of genetic testing, how much information is too much? Genetic counselor Laura Hercher argues that sometimes, selectivity is merited.
Virginia Hughes is “sick of reading about the dangers of the genome.” So she complains over at Slate, eloquently, and I’m sick right with her....
John Hawks ponders the day, very soon to come, when high school students will run their genome sequences in bio lab instead of their blood types. He’s rif...
This isn't something we'll figure out in a couple workshops; it's something the industry and the broader genomics community will need to consider carefully over...
Daniel McArthur and Daniel Vorhaus have a beef: Earlier this month, the Sunday Times published an op-ed piece by Camilla Long critiquing the practice and busine...